News

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023.

“Hundreds of organizations have been selected to join each network. Having been asked to become a member on both networks is a rare opportunity — SRI is honored,” said Kathlynn Brown, president of SRI’s Biosciences division.

Through these memberships, SRI gains access to potential funding and flexible contracting for faster award execution compared to traditional contract processes. This means that people can benefit from advanced healthcare innovations in discovery and treatment without having to wait for years.

The Customer Experience Hub seeks to make healthcare treatments accessible to everyone, from rural areas to cities. The Investor Catalyst Hub seeks to accelerate the broad commercialization of groundbreaking biomedical solutions. The networks utilize an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and minority-serving institutions, to deliver scalable positive healthcare outcomes for all Americans.

SRI delivers bioscience, applied research, and commercial transfer expertise — moving important health technologies from the research lab into the real world.

“SRI’s mission is to make an impact so people can live healthier and safer lives,” said Brown. “We’re proud to be a part of this nationwide health initiative to advance our innovations where they can make a difference. Our work in precision medicine is essential, but without government and commercial support, people, especially in rural and underserved areas, cannot benefit.”

SRI joins a nationwide network of organizations aligned to ARPA-H’s overarching mission of improving health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. ARPANET-H hubs and spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.

“The ARPA-H model is advantageous because the trusted members can move quickly, so the proper healthcare can be delivered faster and safer,” Brown said.

 

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and